Navigation Links
Don't Wait to Innovate: Future Pharmaceuticals Magazine Releases Its Issue on Innovation in IT, Cell-Based Therapy and Supply Chains
Date:9/9/2009

NEW YORK, Sept. 9 /PRNewswire/ -- Future Pharmaceuticals features an exclusive interview with Dave Champagne, Vice President and General Manager of Informatics at Thermo Fisher Scientific, and Thor-Gunnar Steinsli, LIMS Manager and Chief Engineer at HUNT Research Center and Biobank, about data integration: the benefits of data, instrument and enterprise integration strategies and challenges at life sciences companies.

"One of the biggest challenges facing life sciences companies has to do with managing the ever-growing volume of data and connecting all of the disparate sources of data throughout an organization," Champagne said.

"HUNT Biobank is a vivid example of the benefits of this type of integrated solution who helped us secure Microsoft's prestigious Pharmaceutical and Life Sciences Innovation Award in Discovery and Product Innovation (for more information visit http://www.thermo.com/informatics)," Champagne added.

The Director of Global Quality Labs at Eli Lilly, Jackie Larew, is featured in this issue leading an expert panel around issues facing the supply chain. One of the questions she poses to the panel is around the recent concerns we've seen with pet food and milk products tainted with melamine and contaminated heparin entering the U.S. supply chain. "What implications does this have for the way pharmaceutical companies ensure quality from their suppliers with an increasingly global supply chain of raw materials?" Larew asked the panelists.

This edition of FP also delves into the changing world of cell-based therapy. Mark Thiede, Research Fellow with Pfizer for the Genetically Modified Models Center of Emphasis, guest moderates a panel discussion on the future of the cellular therapy industry. Read the piece, Diagnosis: Cell-based Therapy, for their insights.

About Future Pharmaceuticals

Future Pharmaceuticals magazine draws connections between industry leaders and pharmaceutical companies. Future Pharmaceuticals recommends next generation and groundbreaking strategies to ensure success across the enterprise.

About Analysts In Media

AIM Inc., headquartered in New York City, is a leading global provider of high-quality, comprehensive information for the professional and enthusiast markets. Through progressive research, surveys and client case studies from visionaries and leaders in the industry, AIM provides access to its validated knowledge via targeted multi-media channels, publications, events and online services.

For more information, visit www.FuturePharmaUS.com


'/>"/>
SOURCE Future Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Boston University Periodontal Study on Imagenetix Compound Published in The Journal of Periodontology
2. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
3. Interleukin Genetics to Present at the 13th International Conference on Periodontal Research
4. Beike Biotech Adds International Executives to Strengthen Current Technologies and Develop Future Pipeline
5. California Life Science, Business, and Economic Development Experts Discuss Californias Bioscience Future
6. New nanolaser key to future optical computers and technologies
7. Ricardo Launches Consortium to Evaluate Lubricant Challenges of Future Low Carbon Engine Technologies
8. Industry Leaders Will Gather to Discuss the Future of the "Hydrogen Economy" in Washington DC
9. GreenHouse Energy, Governor Schwarzenegger Join in Driving the Future of Fueling in California
10. POET to Outline Cellulosic Ethanol's Present, Future at Brazil's Ethanol Summit 2009
11. Health Strategies Group Forecasts Emerging Trends in Future Sales Force Models at the SPBT 2009 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... regulatory and technical consulting, provides a free webinar on Performing Quality ... 13, 2016 at 12pm CT at no charge. , Incomplete investigations are still ...
Breaking Biology Technology:
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
Breaking Biology News(10 mins):